Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Crispr

Rutgers Scientists Working on CRISPR Technology That Could, Literally, Change the World

New Brunswick, NJ, October 21, 2017 — CRISPR…what’s that?  Senior correspondent David Cruz reports on “NJTV News” that CRISPR is emerging technology that you might be hearing about it yet have little understanding that it has the potential to change pretty much everything and everyone in the world.

Peter Romanienko, the managing director of the Genome Editing Core Facility at Rutgers University, explained, “CRISPR is a programmable nucleus, so the power of it is.

And what makes it work so well for gene editing and some of the techniques we use is this protein can use this small segment of RNA to find a site in the genome and cut it.  And by making this DNA break in the genome is what allows us to introduce sequences and repair.” Continue reading

NIH Panel Approves First Test of CRISPR Editing in Humans; Study to Target Three Types of Cancer

Gene editing crisprBethesda, MD, June 22, 2016The Washington Post reports that a National Institutes of Health (NIH) advisory panel yesterday approved the first human use of the gene-editing technology CRISPR, for a study designed to target three types of cancer and funded by tech billionaire Sean Parker’s new cancer institute.

The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients’ own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma.

The federal Recombinant DNA Advisory Committee approved the Penn proposal unanimously, with one member abstaining.  The experiment still must be approved by the Food and Drug Administration, which regulates clinical trials. Continue reading

Medical Innovation: Scientists Find Form of Crispr Gene Editing with New Capabilities

Gene editing crisprNew York, New York, June 6, 2016 ― Carl Zimmer reports in The New York Times that just a few years ago, Crispr was a cipher — something that sounded to most ears like a device for keeping lettuce fresh.

Today, Crispr-Cas9 is widely known as a powerful way to edit genes. Scientists are deploying it in promising experiments, and a number of companies are already using it to develop drugs to treat conditions ranging from cancer to sickle-cell anemia.

Yet there is still a lot of misunderstanding around it.

Crispr describes a series of DNA sequences discovered in microbes, part of a system to defend against attacking viruses.  Microbes make thousands of forms of Crispr, most of which are just starting to be investigated by scientists.  If they can be harnessed, some may bring changes to medicine that we can barely imagine. Continue reading